<tablegroup Reference='ref' id='id30-----39-----BCMA;18-001678;-20C;INVERTED'><h3 tableHeader='yes'>3.2.1.7.3-2. Drug Product Stability Long-Term Batch 18-001678 for -20C</h3><table class='output-table' border='1' width='100%' pagebreak='true' id='id30-----39-----BCMA;18-001678;-20C;INVERTED1' parent_tablegroup='id30-----39-----BCMA;18-001678;-20C;INVERTED' seq='1'><tr><th columnWidth='11' id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----Time (Months)-----Time (Months)___Time (Months)-----Time (Months)'>Time (Months)</th><th columnWidth='9' id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----Time (Months)-----AEX-HPLC___Anti-CD3 mAb-----AEX-HPLC'>AEX-HPLC</th><th columnWidth='10' id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----Time (Months)-----Appearance___Clarity-----Appearance'>Appearance</th><th columnWidth='10' id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----Time (Months)-----Appearance___Coloration-----Appearance'>Appearance</th><th columnWidth='10' id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----Time (Months)-----Appearance___Visible Particulates-----Appearance'>Appearance</th><th columnWidth='10' id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----Time (Months)-----Biological Activity (Binding ELISA)___Relative Potency-----Biological Activity (Binding ELISA)'>Biological Activity (Binding ELISA)</th><th columnWidth='10' id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----Time (Months)-----CEX-HPLC___Anti-BCMA mAb-----CEX-HPLC'>CEX-HPLC</th><th columnWidth='10' id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----Time (Months)-----CEX-HPLC___Anti-BCMA/Anti-CD3 Bispecific Clip-----CEX-HPLC'>CEX-HPLC</th><th columnWidth='10' id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----Time (Months)-----CGE (non-reducing)___Fragments-----CGE (non-reducing)'>CGE (non-reducing)</th><th columnWidth='12' id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----Time (Months)-----CGE (non-reducing)___Intact IgG-----CGE (non-reducing)'>CGE (non-reducing)</th><th columnWidth='10' id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----Time (Months)-----CGE (non-reducing)___Other-----CGE (non-reducing)'>CGE (non-reducing)</th><th columnWidth='10' id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----Time (Months)-----CGE (reducing)___Fragments-----CGE (reducing)'>CGE (reducing)</th><th columnWidth='10' id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----Time (Months)-----CGE (reducing)___Heavy Chain + Light Chain-----CGE (reducing)'>CGE (reducing)</th><th columnWidth='10' id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----Time (Months)-----CGE (reducing)___Other-----CGE (reducing)'>CGE (reducing)</th><th columnWidth='10' id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----Time (Months)-----Endotoxin___Endotoxin-----Endotoxin'>Endotoxin</th><th columnWidth='10' id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----Time (Months)-----Osmolarity___Osmolarity-----Osmolarity'>Osmolarity</th><th columnWidth='10' id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----Time (Months)-----Peptide Mapping___Identity (Peptide Profile)-----Peptide Mapping'>Peptide Mapping</th><th columnWidth='10' id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----Time (Months)-----SE-HPLC___HMMS-----SE-HPLC'>SE-HPLC</th></tr><tr><th id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----Time (Months)-----Time (Months)___Time (Months)-----Time (Months)'>Time (Months)</th><th id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----Time (Months)-----AEX-HPLC___Anti-CD3 mAb-----Anti-CD3 mAb'>Anti-CD3 mAb</th><th id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----Time (Months)-----Appearance___Clarity-----Clarity'>Clarity</th><th id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----Time (Months)-----Appearance___Coloration-----Coloration'>Coloration</th><th id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----Time (Months)-----Appearance___Visible Particulates-----Visible Particulates'>Visible Particulates</th><th id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----Time (Months)-----Biological Activity (Binding ELISA)___Relative Potency-----Relative Potency'>Relative Potency</th><th id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----Time (Months)-----CEX-HPLC___Anti-BCMA mAb-----Anti-BCMA mAb'>Anti-BCMA mAb</th><th id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----Time (Months)-----CEX-HPLC___Anti-BCMA/Anti-CD3 Bispecific Clip-----Anti-BCMA/Anti-CD3 Bispecific Clip'>Anti-BCMA/Anti-CD3 Bispecific Clip</th><th id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----Time (Months)-----CGE (non-reducing)___Fragments-----Fragments'>Fragments</th><th id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----Time (Months)-----CGE (non-reducing)___Intact IgG-----Intact IgG-aaaaaaaa'>Intact IgG-aaaaaaaa</th><th id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----Time (Months)-----CGE (non-reducing)___Other-----Other'>Other</th><th id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----Time (Months)-----CGE (reducing)___Fragments-----Fragments'>Fragments</th><th id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----Time (Months)-----CGE (reducing)___Heavy Chain + Light Chain-----Heavy Chain + Light Chain'>Heavy Chain + Light Chain</th><th id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----Time (Months)-----CGE (reducing)___Other-----Other'>Other</th><th id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----Time (Months)-----Endotoxin___Endotoxin-----Endotoxin'>Endotoxin</th><th id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----Time (Months)-----Osmolarity___Osmolarity-----Osmolarity'>Osmolarity</th><th id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----Time (Months)-----Peptide Mapping___Identity (Peptide Profile)-----Identity (Peptide Profile)'>Identity (Peptide Profile)</th><th id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----Time (Months)-----SE-HPLC___HMMS-----HMMS'>HMMS</th></tr><tr><th id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----Clinical Acceptance Criteria-----Time (Months)___Time (Months)'>Clinical Acceptance Criteria</th><th id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----Clinical Acceptance Criteria-----AEX-HPLC___Anti-CD3 mAb'>&lt;= 3.0% anti CD3 parent mAb</th><th id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----Clinical Acceptance Criteria-----Appearance___Clarity'>&lt;= 18 NTU</th><th id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----Clinical Acceptance Criteria-----Appearance___Coloration'>Not more intensely colored than level 5 of the color standard</th><th id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----Clinical Acceptance Criteria-----Appearance___Visible Particulates'>Essentially free from visible particulates</th><th id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----Clinical Acceptance Criteria-----Biological Activity (Binding ELISA)___Relative Potency'>50 - 150% potency relative to reference material</th><th id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----Clinical Acceptance Criteria-----CEX-HPLC___Anti-BCMA mAb'>&lt;= 3.0% anti BCMA parent mAb</th><th id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----Clinical Acceptance Criteria-----CEX-HPLC___Anti-BCMA/Anti-CD3 Bispecific Clip'>&lt;= 5.0% Bispecific mAb Clip</th><th id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----Clinical Acceptance Criteria-----CGE (non-reducing)___Fragments'>&lt;= 10.0% fragments</th><th id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----Clinical Acceptance Criteria-----CGE (non-reducing)___Intact IgG'>&gt;= 90.0% IgG</th><th id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----Clinical Acceptance Criteria-----CGE (non-reducing)___Other'>Report Results</th><th id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----Clinical Acceptance Criteria-----CGE (reducing)___Fragments'>-</th><th id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----Clinical Acceptance Criteria-----CGE (reducing)___Heavy Chain + Light Chain'>-</th><th id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----Clinical Acceptance Criteria-----CGE (reducing)___Other'>-</th><th id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----Clinical Acceptance Criteria-----Endotoxin___Endotoxin'>&lt;= 4.3 EU/mg</th><th id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----Clinical Acceptance Criteria-----Osmolarity___Osmolarity'>Report Results</th><th id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----Clinical Acceptance Criteria-----Peptide Mapping___Identity (Peptide Profile)'>Comparable to Reference</th><th id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----Clinical Acceptance Criteria-----SE-HPLC___HMMS'>&lt;= 5.0% HMMS</th></tr><tr><td columnWidth='11' id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----0-----Time (Months)___Time (Months)'>0</td><td columnWidth='9' id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----0-----AEX-HPLC___Anti-CD3 mAb'>NMT 0.1</td><td columnWidth='10' id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----0-----Appearance___Clarity'>4</td><td columnWidth='10' id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----0-----Appearance___Coloration'>&lt;=B9</td><td columnWidth='10' id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----0-----Appearance___Visible Particulates'>Essentially free from visible particulates</td><td columnWidth='10' id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----0-----Biological Activity (Binding ELISA)___Relative Potency'>104</td><td columnWidth='10' id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----0-----CEX-HPLC___Anti-BCMA mAb'>0.2</td><td columnWidth='10' id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----0-----CEX-HPLC___Anti-BCMA/Anti-CD3 Bispecific Clip'>NMT 0.4</td><td columnWidth='10' id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----0-----CGE (non-reducing)___Fragments'>0.4</td><td columnWidth='12' id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----0-----CGE (non-reducing)___Intact IgG'>99.6</td><td columnWidth='10' id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----0-----CGE (non-reducing)___Other'>NMT 0.3</td><td columnWidth='10' id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----0-----CGE (reducing)___Fragments'>0.7</td><td columnWidth='10' id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----0-----CGE (reducing)___Heavy Chain + Light Chain'>99.3</td><td columnWidth='10' id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----0-----CGE (reducing)___Other'>NMT 0.3</td><td columnWidth='10' id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----0-----Endotoxin___Endotoxin'>NMT 0.1</td><td columnWidth='10' id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----0-----Osmolarity___Osmolarity'>315</td><td columnWidth='10' id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----0-----Peptide Mapping___Identity (Peptide Profile)'>Comparable to Reference</td><td columnWidth='10' id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----0-----SE-HPLC___HMMS'>NMT 0.2</td></tr><tr><td id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----1-----Time (Months)___Time (Months)'>1</td><td id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----1-----AEX-HPLC___Anti-CD3 mAb'>0.1</td><td id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----1-----Appearance___Clarity'>4</td><td id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----1-----Appearance___Coloration'>&lt;=B8</td><td id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----1-----Appearance___Visible Particulates'>Essentially free from visible particulates</td><td id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----1-----Biological Activity (Binding ELISA)___Relative Potency'>96</td><td id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----1-----CEX-HPLC___Anti-BCMA mAb'>NMT 0.1</td><td id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----1-----CEX-HPLC___Anti-BCMA/Anti-CD3 Bispecific Clip'>0.5</td><td id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----1-----CGE (non-reducing)___Fragments'>0.4</td><td id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----1-----CGE (non-reducing)___Intact IgG'>99.6</td><td id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----1-----CGE (non-reducing)___Other'>NMT 0.3</td><td id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----1-----CGE (reducing)___Fragments'>1.0</td><td id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----1-----CGE (reducing)___Heavy Chain + Light Chain'>99.0</td><td id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----1-----CGE (reducing)___Other'>NMT 0.3</td><td id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----1-----Endotoxin___Endotoxin'>NR</td><td id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----1-----Osmolarity___Osmolarity'>NR</td><td id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----1-----Peptide Mapping___Identity (Peptide Profile)'>NR</td><td id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----1-----SE-HPLC___HMMS'>NMT 0.2</td></tr><tr><td id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----3-----Time (Months)___Time (Months)'>3</td><td id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----3-----AEX-HPLC___Anti-CD3 mAb'>0.3</td><td id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----3-----Appearance___Clarity'>5</td><td id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----3-----Appearance___Coloration'>&lt;=B9</td><td id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----3-----Appearance___Visible Particulates'>Essentially free from visible particulates</td><td id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----3-----Biological Activity (Binding ELISA)___Relative Potency'>94</td><td id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----3-----CEX-HPLC___Anti-BCMA mAb'>NMT 0.1</td><td id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----3-----CEX-HPLC___Anti-BCMA/Anti-CD3 Bispecific Clip'>0.6</td><td id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----3-----CGE (non-reducing)___Fragments'>1.3</td><td id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----3-----CGE (non-reducing)___Intact IgG'>98.7</td><td id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----3-----CGE (non-reducing)___Other'>NMT 0.3</td><td id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----3-----CGE (reducing)___Fragments'>0.9</td><td id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----3-----CGE (reducing)___Heavy Chain + Light Chain'>99.1</td><td id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----3-----CGE (reducing)___Other'>NMT 0.3</td><td id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----3-----Endotoxin___Endotoxin'>NR</td><td id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----3-----Osmolarity___Osmolarity'>NR</td><td id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----3-----Peptide Mapping___Identity (Peptide Profile)'>NR</td><td id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----3-----SE-HPLC___HMMS'>NMT 0.2</td></tr><tr><td id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----6-----Time (Months)___Time (Months)'>6</td><td id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----6-----AEX-HPLC___Anti-CD3 mAb'>NMT 0.1</td><td id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----6-----Appearance___Clarity'>4</td><td id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----6-----Appearance___Coloration'>&lt;=B7</td><td id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----6-----Appearance___Visible Particulates'>Essentially free from visible particulates</td><td id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----6-----Biological Activity (Binding ELISA)___Relative Potency'>98</td><td id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----6-----CEX-HPLC___Anti-BCMA mAb'>0.1</td><td id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----6-----CEX-HPLC___Anti-BCMA/Anti-CD3 Bispecific Clip'>0.9</td><td id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----6-----CGE (non-reducing)___Fragments'>2.6</td><td id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----6-----CGE (non-reducing)___Intact IgG'>97.4</td><td id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----6-----CGE (non-reducing)___Other'>NMT 0.3</td><td id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----6-----CGE (reducing)___Fragments'>1.7</td><td id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----6-----CGE (reducing)___Heavy Chain + Light Chain'>98.3</td><td id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----6-----CGE (reducing)___Other'>NMT 0.3</td><td id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----6-----Endotoxin___Endotoxin'>NR</td><td id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----6-----Osmolarity___Osmolarity'>NR</td><td id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----6-----Peptide Mapping___Identity (Peptide Profile)'>NR</td><td id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----6-----SE-HPLC___HMMS'>NMT 0.2</td></tr></table><br/><table class='output-table' border='1' width='100%' pagebreak='true' id='id30-----39-----BCMA;18-001678;-20C;INVERTED2' parent_tablegroup='id30-----39-----BCMA;18-001678;-20C;INVERTED' seq='2'><tr><th columnWidth='11' id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----Time (Months)-----Time (Months)___Time (Months)-----Time (Months)'>Time (Months)</th><th columnWidth='10' id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----Time (Months)-----SE-HPLC___Monomer-----SE-HPLC'>SE-HPLC</th><th columnWidth='10' id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----Time (Months)-----Sterility___Sterility-----Sterility'>Sterility</th><th columnWidth='10' id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----Time (Months)-----Subvisible Particles___Subvisible Particles-----Subvisible Particles'>Subvisible Particles</th><th columnWidth='10' id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----Time (Months)-----Subvisible Particles___Subvisible Particles &gt;= 10&#xc3;&#x82;&#xc2;&#xb5;m-----Subvisible Particles'>Subvisible Particles</th><th columnWidth='10' id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----Time (Months)-----Subvisible Particles___Subvisible Particles &gt;= 25&#xc3;&#x82;&#xc2;&#xb5;m-----Subvisible Particles'>Subvisible Particles</th><th columnWidth='10' id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----Time (Months)-----UV Spectroscopy___Protein Concentration-----UV Spectroscopy'>UV Spectroscopy</th><th columnWidth='10' id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----Time (Months)-----iCE___Acidic Species-----iCE'>iCE</th><th columnWidth='10' id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----Time (Months)-----iCE___Basic Species-----iCE'>iCE</th><th columnWidth='10' id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----Time (Months)-----iCE___Main Species-----iCE'>iCE</th></tr><tr><th id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----Time (Months)-----Time (Months)___Time (Months)-----Time (Months)'>Time (Months)</th><th id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----Time (Months)-----SE-HPLC___Monomer-----Monomer'>Monomer</th><th id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----Time (Months)-----Sterility___Sterility-----Sterility'>Sterility</th><th id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----Time (Months)-----Subvisible Particles___Subvisible Particles-----Subvisible Particles'>Subvisible Particles</th><th id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----Time (Months)-----Subvisible Particles___Subvisible Particles &gt;= 10&#xc3;&#x82;&#xc2;&#xb5;m-----Subvisible Particles &gt;= 10&#xb5;m'>Subvisible Particles &gt;= 10&#xb5;m</th><th id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----Time (Months)-----Subvisible Particles___Subvisible Particles &gt;= 25&#xc3;&#x82;&#xc2;&#xb5;m-----Subvisible Particles &gt;= 25&#xb5;m'>Subvisible Particles &gt;= 25&#xb5;m</th><th id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----Time (Months)-----UV Spectroscopy___Protein Concentration-----Protein Concentration'>Protein Concentration</th><th id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----Time (Months)-----iCE___Acidic Species-----Acidic Species'>Acidic Species</th><th id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----Time (Months)-----iCE___Basic Species-----Basic Species'>Basic Species</th><th id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----Time (Months)-----iCE___Main Species-----Main Species'>Main Species</th></tr><tr><th id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----Clinical Acceptance Criteria-----Time (Months)___Time (Months)'>Clinical Acceptance Criteria</th><th id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----Clinical Acceptance Criteria-----SE-HPLC___Monomer'>&gt;= 90.0% monomer</th><th id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----Clinical Acceptance Criteria-----Sterility___Sterility'>No growth detected</th><th id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----Clinical Acceptance Criteria-----Subvisible Particles___Subvisible Particles'>Meets compendial requirements</th><th id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----Clinical Acceptance Criteria-----Subvisible Particles___Subvisible Particles &gt;= 10&#xc3;&#x82;&#xc2;&#xb5;m'>Report Results</th><th id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----Clinical Acceptance Criteria-----Subvisible Particles___Subvisible Particles &gt;= 25&#xc3;&#x82;&#xc2;&#xb5;m'>Report Results</th><th id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----Clinical Acceptance Criteria-----UV Spectroscopy___Protein Concentration'>10.0 +/- 1.0 mg/mL</th><th id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----Clinical Acceptance Criteria-----iCE___Acidic Species'>Report Results</th><th id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----Clinical Acceptance Criteria-----iCE___Basic Species'>Report Results</th><th id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----Clinical Acceptance Criteria-----iCE___Main Species'>Report Results</th></tr><tr><td columnWidth='11' id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----0-----Time (Months)___Time (Months)'>0</td><td columnWidth='10' id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----0-----SE-HPLC___Monomer'>99.8</td><td columnWidth='10' id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----0-----Sterility___Sterility'>No growth detected</td><td columnWidth='10' id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----0-----Subvisible Particles___Subvisible Particles'>Meets compendial requirements</td><td columnWidth='10' id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----0-----Subvisible Particles___Subvisible Particles &gt;= 10&#xc3;&#x82;&#xc2;&#xb5;m'>15</td><td columnWidth='10' id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----0-----Subvisible Particles___Subvisible Particles &gt;= 25&#xc3;&#x82;&#xc2;&#xb5;m'>&lt;1</td><td columnWidth='10' id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----0-----UV Spectroscopy___Protein Concentration'>10.4</td><td columnWidth='10' id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----0-----iCE___Acidic Species'>39.8</td><td columnWidth='10' id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----0-----iCE___Basic Species'>14.6</td><td columnWidth='10' id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----0-----iCE___Main Species'>45.6</td></tr><tr><td id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----1-----Time (Months)___Time (Months)'>1</td><td id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----1-----SE-HPLC___Monomer'>99.9</td><td id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----1-----Sterility___Sterility'>NR</td><td id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----1-----Subvisible Particles___Subvisible Particles'>NR</td><td id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----1-----Subvisible Particles___Subvisible Particles &gt;= 10&#xc3;&#x82;&#xc2;&#xb5;m'>NR</td><td id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----1-----Subvisible Particles___Subvisible Particles &gt;= 25&#xc3;&#x82;&#xc2;&#xb5;m'>NR</td><td id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----1-----UV Spectroscopy___Protein Concentration'>10.7</td><td id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----1-----iCE___Acidic Species'>39.5</td><td id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----1-----iCE___Basic Species'>14.2</td><td id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----1-----iCE___Main Species'>46.2</td></tr><tr><td id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----3-----Time (Months)___Time (Months)'>3</td><td id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----3-----SE-HPLC___Monomer'>99.8</td><td id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----3-----Sterility___Sterility'>NR</td><td id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----3-----Subvisible Particles___Subvisible Particles'>NR</td><td id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----3-----Subvisible Particles___Subvisible Particles &gt;= 10&#xc3;&#x82;&#xc2;&#xb5;m'>NR</td><td id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----3-----Subvisible Particles___Subvisible Particles &gt;= 25&#xc3;&#x82;&#xc2;&#xb5;m'>NR</td><td id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----3-----UV Spectroscopy___Protein Concentration'>10.4</td><td id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----3-----iCE___Acidic Species'>38.7</td><td id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----3-----iCE___Basic Species'>14.9</td><td id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----3-----iCE___Main Species'>46.3</td></tr><tr><td id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----6-----Time (Months)___Time (Months)'>6</td><td id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----6-----SE-HPLC___Monomer'>99.7</td><td id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----6-----Sterility___Sterility'>NR</td><td id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----6-----Subvisible Particles___Subvisible Particles'>Meets compendial requirements</td><td id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----6-----Subvisible Particles___Subvisible Particles &gt;= 10&#xc3;&#x82;&#xc2;&#xb5;m'>1</td><td id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----6-----Subvisible Particles___Subvisible Particles &gt;= 25&#xc3;&#x82;&#xc2;&#xb5;m'>0</td><td id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----6-----UV Spectroscopy___Protein Concentration'>10.4</td><td id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----6-----iCE___Acidic Species'>43.0</td><td id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----6-----iCE___Basic Species'>14.1</td><td id='id30-----39-----BCMA;18-001678;-20C;INVERTED-----6-----iCE___Main Species'>43.0</td></tr></table><br/></tablegroup><br/>